Advisors Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Advisors Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$77.7K	Buy	3,991 +49	+1%	+$888	﹤0.01%	1261
2026 Q1	$73.5K	Sell	3,942 -50	-1%	-$828	﹤0.01%	1265
2025 Q4	$52.6K	Sell	3,992 -2	-0.1%	-$24	﹤0.01%	1303
2025 Q3	$28.6K	Sell	3,994 -15	-0.4%	-$782	﹤0.01%	1333
2025 Q2	$189K	Hold	4,009	–	–	﹤0.01%	1124
2025 Q1	$157K	Buy	4,009 +1,803	+82%	+$77.7K	﹤0.01%	1135
2024 Q4	$119K	Buy	+2,206	New	+$113K	﹤0.01%	1195

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Advisors Asset Management's MLTX Position: Q2 2026 in Review

Advisors Asset Management increased its MoonLake Immunotherapeutics (MLTX) stake by 1.2% in Q2 2026, buying an estimated $888 and bringing the position to 3,991 shares worth $77.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1261.

Advisors Asset Management first reported a position in MLTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $189K in Q2 2025. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Advisors Asset Management held 3,991 shares of MoonLake Immunotherapeutics worth $77.7K as of Q2 2026.
Advisors Asset Management bought 49 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $888.
MoonLake Immunotherapeutics made up ﹤0.01% of Advisors Asset Management's portfolio in Q2 2026, its #1261 holding.
Advisors Asset Management first reported a position in MoonLake Immunotherapeutics in Q4 2024 and has held it in 7 quarters since.
Advisors Asset Management's MoonLake Immunotherapeutics position peaked at $189K in Q2 2025.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.